The CREATE trial is an example of a biomarker-driven basket trial, leveraging on the demonstrated biological activity of crizotinib in preclinical work and applying that to sarcoma subtypes with known genetic alterations resulting in the upregulation of ALK and/or MET. Here, ALK is linked to sarcoma.